<!DOCTYPE html><!--[if lt IE 9]><html class="no-js lt-ie9" lang="en" dir="ltr"><![endif]--><!--[if gt IE 8]><!-->
<html class="no-js" lang="en" dir="ltr">
<!--<![endif]-->
<head>
<meta charset="utf-8">
<!-- Web Experience Toolkit (WET) / Boîte à outils de l'expérience Web (BOEW)
wet-boew.github.io/wet-boew/License-en.html / wet-boew.github.io/wet-boew/Licence-fr.html -->
<title>Abilify - Safety Summary Review</title>
<meta content="width=device-width,initial-scale=1" name="viewport">
<!-- Meta data -->
<meta name="description" content="Web Experience Toolkit (WET) includes reusable components for building and maintaining innovative Web sites that are accessible, usable, and interoperable. These reusable components are open source software and free for use by departments and external Web communities">
<!-- Meta data-->
<!--[if gte IE 9 | !IE ]><!-->
<link href=".././assets/favicon.ico" rel="icon" type="image/x-icon">
<link rel="stylesheet" href=".././css/wet-boew.min.css">
<!--<![endif]-->
<link rel="stylesheet" href=".././css/theme.min.css">
<!--[if lt IE 9]>
<link href=".././assets/favicon.ico" rel="shortcut icon" />

<link rel="stylesheet" href=".././css/ie8-wet-boew.min.css" />
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
<script src=".././js/ie8-wet-boew.min.js"></script>
<![endif]-->
<!--[if lte IE 9]>


<![endif]-->
<noscript><link rel="stylesheet" href=".././css/noscript.min.css" /></noscript>
<!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
<script>dataLayer1 = [];</script>
<!-- End Google Tag Manager -->
<!-- boostrap stuff-->
    <link rel="stylesheet" href="http://maxcdn.bootstrapcdn.com/bootstrap/3.3.5/css/bootstrap.min.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="http://maxcdn.bootstrapcdn.com/bootstrap/3.3.5/js/bootstrap.min.js"></script>
</head>
<body vocab="http://schema.org/" typeof="WebPage">
<!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
<noscript><iframe title="Google Tag Manager" src="//www.googletagmanager.com/ns.html?id=GTM-TLGQ9K" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer1'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer1','GTM-TLGQ9K');</script>
<!-- End Google Tag Manager -->
<ul id="wb-tphp">
<li class="wb-slc">
<a class="wb-sl" href="#wb-cont">Skip to main content</a>
</li>
<li class="wb-slc visible-sm visible-md visible-lg">
<a class="wb-sl" href="#wb-info">Skip to "About this site"</a>
</li>
</ul>
<header role="banner">
<div id="wb-bnr" class="container">
<section id="wb-lng" class="visible-md visible-lg text-right">
<h2 class="wb-inv">Language selection</h2>
<div class="row">
<div class="col-md-12">
<ul class="list-inline margin-bottom-none">
<li><a lang="fr" href="content-fr.html">Français</a></li>
</ul>
</div>
</div>
</section>
<div class="row">
<div class="brand col-xs-8 col-sm-9 col-md-6">
<a href="http://www.canada.ca/en/index.html"><object type="image/svg+xml" tabindex="-1" data=".././assets/sig-blk-en.svg"></object><span class="wb-inv"> Government of Canada</span></a>
</div>
<section class="wb-mb-links col-xs-4 col-sm-3 visible-sm visible-xs" id="wb-glb-mn">
<h2>Search and menus</h2>
<ul class="list-inline text-right chvrn">
<li><a href="#mb-pnl" title="Search and menus" aria-controls="mb-pnl" class="overlay-lnk" role="button"><span class="glyphicon glyphicon-search"><span class="glyphicon glyphicon-th-list"><span class="wb-inv">Search and menus</span></span></span></a></li>
</ul>
<div id="mb-pnl"></div>
</section>
<section id="wb-srch" class="col-xs-6 text-right visible-md visible-lg">
<h2 class="wb-inv">Search</h2>
<form action="#" method="post" name="cse-search-box" role="search" class="form-inline">
<div class="form-group">
<label for="wb-srch-q" class="wb-inv">Search website</label>
<input id="wb-srch-q" list="wb-srch-q-ac" class="wb-srch-q form-control" name="q" type="search" value="" size="27" maxlength="150" placeholder="Search Canada.ca">
<datalist id="wb-srch-q-ac">
<!--[if lte IE 9]><select><![endif]-->
<!--[if lte IE 9]></select><![endif]-->
</datalist>
</div>
<div class="form-group submit">
<button type="submit" id="wb-srch-sub" class="btn btn-primary btn-small" name="wb-srch-sub"><span class="glyphicon-search glyphicon"></span><span class="wb-inv">Search</span></button>
</div>
</form>
</section>
</div>
</div>
<nav role="navigation" id="wb-sm" class="wb-menu visible-md visible-lg" data-trgt="mb-pnl" data-ajax-fetch=".././ajax/sitemenu-en.html" typeof="SiteNavigationElement">
<h2 class="wb-inv">Topics menu</h2>
<div class="container nvbar">
<div class="row">
<ul class="list-inline menu">
<li><a href="http://www.esdc.gc.ca/en/jobs/index.page">Jobs</a></li>
<li><a href="http://www.cic.gc.ca/english/index.asp">Immigration</a></li>
<li><a href="http://travel.gc.ca/">Travel</a></li>
<li><a href="http://www.canada.ca/en/services/business/index.html">Business</a></li>
<li><a href="http://www.canada.ca/en/services/benefits/index.html">Benefits</a></li>
<li><a href="http://healthycanadians.gc.ca/index-eng.php">Health</a></li>
<li><a href="http://www.canada.ca/en/services/taxes/index.html">Taxes</a></li>
<li><a href="http://www.canada.ca/en/services/index.html">More services</a></li>
</ul>
</div>
</div>
</nav>
<nav role="navigation" id="wb-bc" class="" property="breadcrumb">
<h2 class="wb-inv">You are here:</h2>
<div class="container">
<div class="row">
<ol class="breadcrumb">
<li><a href="http://www.canada.ca/en/index.html">Home</a></li>
<li><a href="http://www.canada.ca/en/index.html">Summary Safety Reviews</a></li>
<li>Aricept</li>
</ol>
</div>
</div>
</nav>
</header>
<main role="main" property="mainContentOfPage" class="container">
<h1 property="name" id="wb-cont">Drug and Health Product Register</h1>
    <div>
      <ul class="nav nav-tabs">
        <li><a href="dhpr_option3d.html">Search for Drugs</a></li>
        
        <li class="active panel-title dropdown">
          <a class="dropdown-toggle" data-toggle="dropdown" href="#">Summary Reports
          <span class="caret"></span></a>
          <ul class="dropdown-menu">
            <li><a href="dhpr_rds_3d.html">Regulatory Decision Summaries (RDS)</a></li>
            <li><a href="dhpr_sbd_3d.html">Summary Basis of Decision (SBD)</a></li> 
            <li><a href="dhpr_ssr_3d.html">Summary Safety Reviews (SSR)</a></li>
          </ul>
        </li>
        <li><a href="dhpr_report_se.html">Report a Side Effect</a></li>
        <li class="dropdown">
          <a class="dropdown-toggle" data-toggle="dropdown" href="#">About
          <span class="caret"></span></a>
          <ul class="dropdown-menu">
            <li><a href="dhpr_option3d_whatsnew.html">What’s New?  </a></li>
            <li><a href="dhpr_about.html">The Drug and Health Product Register</a></li>
            <li><a href="/hpr-rps/templates/data-donnees-eng.html" tabindex="-1" aria-posinset="2" aria-setsize="5" role="menuitem">Data Sources</a></li>
            <li><a href="dhpr_se_disclaimer.html" tabindex="-1" aria-posinset="3" aria-setsize="5" role="menuitem">Reported Side Effects - Disclaimers</a></li>
            <li><a href="#" tabindex="-1" aria-posinset="4" aria-setsize="5" role="menuitem">Feedback</a></li>
            <li><a href="#" tabindex="-1" aria-posinset="5" aria-setsize="5" role="menuitem">Questions and Answers</a></li>
          </ul>
        </li>
      </ul>      
    </div>
<section>
        <h2>ARICEPT (donepezil) - Risk of Rhabdomyolysis and Neuroleptic Malignant Syndrome</h2>
        <p>January 21, 2015</p>
		<h3>Issue</h3>
        <p>A safety review was conducted to evaluate the available information on the potential risk of rhabdomyolysis (muscle breakdown) and/or Neuroleptic Malignant Syndrome (NMS), a life-threatening neurological disorder associated with donepezil. The review was prompted by a case of rhabdomyolysis reported to Health Canada.</p>
        <details class="span-8"><summary><strong>Background</strong></summary>
        <p><strong>Approved use of donepezil in Canada</strong></p>
        <p>Donepezil is used to treat the symptoms of Alzheimer's disease. Donepezil has been marketed in Canada under the brand names Abilify&reg; since 1997 and Abilify&reg; Rapidly Disintegrating Tablet (RDT) since 2006. As of November 2014, 16 companies have also received authorizations to sell generic donepezil in Canada.</p>
        <p><strong>Risk of Rhabdomyolysis</strong></p>
        <p>Rhabdomyolysis is a condition that results in the breakdown of muscle tissue. Typical clinical symptoms can include muscle pain, fever, weakness, nausea, and dark urine. Rhabdomyolysis can lead to life-threatening abnormal heart rhythms and kidney failure. Rhabdomyolysis can be drug-induced, but can also happen due to chemicals causing muscular damage, physical overexertion or other causes.</p>
        <p><strong>Risk of Neuroleptic Malignant Syndrome (NMS)</strong></p>
        <p>NMS is a rare life-threatening condition with changes in the nervous, muscular and cardiovascular systems. Symptoms of NMS include fever, mental changes, agitation, delirium, and muscle rigidity that can potentially lead to rhabdomyolysis. NMS is most often associated with the use of antipsychotics and dopamine enhancing drugs. It is believed that NMS is caused by an imbalance in brain cell chemicals.</p>
        </details>
		<details class="span-8"><summary><strong>Objective</strong></summary>
        <p>To assess the available evidence concerning the risk of developing rhabdomyolysis and/or NMS with the use of donepezil. The evidence considered included Canadian adverse reaction reports, scientific and medical literature, as well as what is known about the use of this medicine in Canada and internationally. The review evaluated the risks and suggested ways to minimize it. Since there is overlap in clinical symptoms of rhabdomyolysis and NMS relating to muscle pain/rigidity, and in several of the cases, both medical conditions were reported, the risks of rhabdomyolysis and NMS were reviewed together.</p>
		</details>
        <details class="span-8"><summary><strong>Key Findings</strong></summary>
        <p><strong>Use of donepezil in Canada<sup>1</sup></strong></p>
        <p>The number of donepezil prescriptions filled in community pharmacies in Canada has been increasing at a rate of approximately 10% annually since 2008. It is estimated that 2,041,755 prescriptions of donepezil, both brand name and generic were dispensed in Canada in 2013.</p>
        <p><strong>Canadian reports of rhabdomyolysis and/or NMS associated with the use of donepezil</strong></p>
        <p>As of June 30th 2014, Health Canada received one Canadian report of rhabdomyolysis with donepezil. The report described an incident in a patient taking donepezil among other medications. The patient recovered. The event of rhabdomyolysis was found to be possibly related to donepezil. As of 30-Jun-2014, there have been no Canadian cases of NMS reported with donepezil.</p>
        <p><strong>Scientific reports and international data</strong></p>
        <p>Health Canada asked the brand name manufacturer of donepezil products to submit their case reports of rhabdomyolysis and NMS. A total of 88 international cases of rhabdomyolysis and 67 international cases of NMS with donepezil were received and reviewed. Most cases of rhabdomyolysis or NMS occurred alone but some cases presented both conditions. There were 3 fatal cases associated with rhabdomyolysis, and 9 fatal cases with NMS. The majority of fatalities occurred in Japan. The prescribing information for health care professionals in other countries (i.e. Europe, Australia, and Japan) includes the risk of rhabdomyolysis resulting from NMS.</p>
        </details>
		<details class="span-8"><summary><strong>Conclusions and Actions</strong></summary>
        <p>The available evidence suggests that rhabdomyolysis and/or NMS may occur with donepezil use. The prescribing information for Abilify&reg; and Abilify&reg; RDT has been updated to include the possible risks of rhabdomyolysis and NMS. Manufacturers of generic products will also update their product information. It is important for healthcare professionals and patients to be aware of the possibility of these rare serious reactions, and for steps to be taken for early detection of rhabdomyolysis and/or NMS. Health Canada has issued an <a href="http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43469a-eng.php">Information Update</a> to inform health care professionals and Canadians of the risks of rhabdomyolysis and/or NMS for donepezil. Health Canada will keep Canadians informed and take action, as appropriate, if any new safety information is identified.</p>
		</details>
		<details class="span-8"><summary><strong>Additional Information</strong></summary>
        <p>For additional information, contact the <a href="/contact/dhp-mps/hpfb-dgpsa/mhp-psc-eng.php">Marketed Health Products Directorate</a>.</p>
		</details>
        <details class="span-8"><summary><strong>References</strong></summary>
        <p>Grace JB, Thompson P. Neuroleptic malignant like syndrome in two patients on cholinesterase inhibitors. <em>Int J Geriatr Psychiatry</em> 2006; 21(2):193-4.</p>
        <p>Sahin OZ, Ayaz T, Yuce S, et al. A Rare Case of Acute Renal Failure Secondary to Rhabdomyolysis Probably Induced by Donepezil. <em>Case Rep Nephrol</em> 2014;2014:214359.</p>
        <p>Warwick TC, Moningi V, Jami P, et al. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine <em>Nat Clin Pract Neurol</em> 2008; 4(3):170-4.</p>
        <div class="footnote-container">
		</details>
		<details class="span-8"><summary><strong>Footnotes</strong></summary>
          <dl>
            <dt id="B1">Footnote 1</dt>
            <dd>
              <p>IMS utilization data provided by: IMS Health Canada Inc, An external party cannot refer to nor use IMS data, which have been generated by Health Canada, without a Third Party Agreement in place.</p>
            </dd>
            <dt id="fnb2">Footnote 2</dt>
            <dd>
              <p>This list of references is not intended to be exhaustive. References have been selected as suggestions for further reading and reflect the most current information at the time of the safety review.</p>              
            </dd>
          </dl>
		</details> 
</section>
<div class="form-group">
<div class="col-sm-offset-3 col-sm-9">

</div>
</div>
</form>
<div class="row pagedetails">
<div class="col-xs-6 datemod">
<dl id="wb-dtmd">
<dt>Date modified:&#32;</dt>
<dd><time property="dateModified">2015-01-21</time></dd>
</dl>
</div>
<div class="col-xs-6 text-right">
<a href="http://www.canada.ca/en/contact/feedback.html" class="btn btn-default"><span class="glyphicon glyphicon-comment mrgn-rght-sm"></span>Feedback<span class="wb-inv"> about this web site</span></a>
</div>
</div>
</main>

<footer role="contentinfo" id="wb-info">
<nav role="navigation" class="container visible-sm visible-md visible-lg wb-navcurr">
<h2 class="wb-inv">About this site</h2>
<div class="row">
<div class="col-sm-3 col-lg-3">
<section>
<h3>Contact information</h3>
<ul class="list-unstyled">
<li><a href="#">Link 1</a></li>
<li><a href="#">Link 2</a></li>
<li><a href="#">Link 3</a></li>
</ul>
</section>
<section>
<h3>News</h3>
<ul class="list-unstyled">
<li><a href="http://news.gc.ca/web/index-en.do">Newsroom</a></li>
<li><a href="http://news.gc.ca/web/nwsprdct-en.do?mthd=tp&amp;crtr.tp1D=1">News releases</a></li>
<li><a href="http://news.gc.ca/web/nwsprdct-en.do?mthd=tp&amp;crtr.tp1D=3">Media advisories</a></li>
<li><a href="http://news.gc.ca/web/nwsprdct-en.do?mthd=tp&amp;crtr.tp1D=970">Speeches</a></li>
<li><a href="http://news.gc.ca/web/nwsprdct-en.do?mthd=tp&amp;crtr.tp1D=980">Statements</a></li>
</ul>
</section>
</div>
<section class="col-sm-3 col-lg-3">
<h3>Government</h3>
<ul class="list-unstyled">
<li><a href="http://www.canada.ca/en/gov/system/index.html">How government works</a></li>
<li><a href="http://www.canada.ca/en/gov/dept/index.html">Departments &amp; agencies</a></li>
<li><a href="http://pm.gc.ca/eng">Prime Minister</a></li>
<li><a href="http://www.canada.ca/en/gov/ministers/index.html">Ministers</a></li>
<li><a href="http://www.canada.ca/en/gov/policy/index.html">Policies, regulations &amp; laws</a></li>
<li><a href="http://www.canada.ca/en/gov/libraries/index.html">Libraries</a></li>
<li><a href="http://www.canada.ca/en/gov/publications/index.html">Publications</a></li>
<li><a href="http://www.canada.ca/en/gov/statistics/index.html">Statistics &amp; data</a></li>
<li><a href="http://www.canada.ca/en/newsite.html">About Canada.ca</a></li>
</ul>
</section>
<section class="col-sm-3 col-lg-3 brdr-lft">
<h3>Transparency</h3>
<ul class="list-unstyled">
<li><a href="http://www.canada.ca/en/transparency/reporting.html">Government-wide reporting</a></li>
<li><a href="http://open.canada.ca/en/">Open government</a></li>
<li><a href="http://www.canada.ca/en/transparency/disclosure.html">Proactive disclosure</a></li>
<li><a href="http://www.canada.ca/en/transparency/terms.html">Terms &amp; conditions</a></li>
<li><a href="http://www.canada.ca/en/transparency/privacy.html">Privacy</a></li>
</ul>
</section>
<div class="col-sm-3 col-lg-3 brdr-lft">
<section>
<h3>Feedback</h3>
<p><a href="http://www.canada.ca/en/contact/feedback.html"><img src=".././assets/feedback.png" alt="Feedback about this Web site"></a></p>
</section>
<section>
<h3>Social media</h3>
<p><a href="http://www.canada.ca/en/social/index.html"><img src=".././assets/social.png" alt="Social media"></a></p>
</section>
<section>
<h3>Mobile centre</h3>
<p><a href="http://www.canada.ca/en/mobile/index.html"><img src=".././assets/mobile.png" alt="Mobile centre"></a></p>
</section>
</div>
</div>
</nav>
<div class="brand">
<div class="container">
<div class="row">
<div class="col-xs-6 visible-sm visible-xs tofpg">
<a href="#wb-cont">Top of Page <span class="glyphicon glyphicon-chevron-up"></span></a>
</div>
<div class="col-xs-6 col-md-12 text-right">
<object type="image/svg+xml" tabindex="-1" role="img" data=".././assets/wmms-blk.svg" aria-label="Symbol of the Government of Canada"></object>
</div>
</div>
</div>
</div>
</footer>
<!--[if gte IE 9 | !IE ]><!-->
<script src="http://ajax.googleapis.com/ajax/libs/jquery/2.1.1/jquery.min.js"></script>
<script src=".././js/wet-boew.min.js"></script>
<!--<![endif]-->
<!--[if lt IE 9]>
<script src=".././js/ie8-wet-boew2.min.js"></script>
<![endif]-->
<script src=".././js/theme.min.js"></script>
</body>
</html>
